Exosomes, enriched with cancer-specific nucleic acids and proteins, have emerged as key intercellular communicators for orchestrating a tripartite axis of the tumor microenvironment (TME). They contribute significantly to tumor progression, particularly through their involvement in drug resistance, immune suppression, and metastasis. Recently, extensive research has mapped isolated functions to integrated perspective on how exosomal cargo mediates the complex crosstalk between these three important avenues of tumor survival. This begins by outlining the fundamental mechanisms of exosome biogenesis, cargo sorting and release that are frequently hijacked by cancer cells. This review then examines the exosome-mediated transfer of drug efflux pumps, non-coding RNAs, and metabolic enzymes from drug-resistant tumor cells to drug-sensitive cells. Subsequently, this review explore how tumor derived exosomes influence the premetastatic niche to support angiogenesis, including the horizontal transfer of key cytokines and growth factors. Additionally, this review details the role of tumor derived exosomes in shaping an immunosuppressive TME, especially their capacity to modulate T-cell function, polarize myeloid cells, and influence immune checkpoint signalling. Finally , we discuss emerging therapeutic strategies aimed at intercepting or reprogramming exosomal cargo to potentially prevent metastasis, sensitize tumor to therapeutics , and counteract immune evasion. By shifting the focus from isolated mechanisms to the interconnected roles of exosomes, this review aims to inform the rational design of next-generation exosome targeted and exosome based cancer therapeutics.
RamaRao Malla, G. P. Nagaraju· Biochemical Pharmacology· 0 citations
Breast cancer is the most frequently reported cancer in women, with high mortality and morbidity globally. Paclitaxel, doxorubicin, tamoxifen, cisplatin, and 5-fluorouracil are cornerstones of standard-of-care treatment for primary and advanced breast cancers, targeting distinct molecular mechanisms. However, the evolution of acquired resistance primarily leads to treatment failure and progression to metastasis, ultimately to patient mortality. Furthermore, their effectiveness is limited by potential toxicities in various organs. These limitations present an extreme challenge for the management of breast cancer at the advanced stage. This review uncovers recent updates on acquired resistance mechanisms toward standard-of-care treatments driven by deeply rooted heterogeneity and aggressive nature through direct counteracting of its core action, hyperactivation of survival pathways, silencing of core cell death pathways, derepressing the expression of multidrug resistance proteins, metabolic reprogramming, epigenetic modifications, and exosome-mediated horizontal transfer of resistance phenotype. In addition, we discuss recent updates on potential strategies to overcome resistance and toxicities induced by standard-of-care treatments. Ultimately, this review helps to identify novel strategies targeting pathways to reverse resistance and reduce toxicity in breast cancer patients.
Anuveda Sree Samudrala, G. P. Nagaraju, RamaRao Malla· Biochimica et biophysica act...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.